Press releaseGlobe Newswire
Zyversa Therapeutics
ZVSA · NASDAQ
$0.001+$0.0008 (+400.00%)TodayMarket closed ·
Prev close $0.0002
Latest news
- Press releaseGlobe Newswire
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
- News
ZyVersa Therapeutics Releases Mid-Year Shareholder Letter Highlighting Recent Corporate Developments And R&D Progress Including Closing Two Financial Transactions Providing Access To $12M In Capital
- Press releaseGlobe Newswire
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
- NewsVandana Singh
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?
- News
ZyVersa Therapeutics Provides Regulatory And Product Support For FDA-Authorized Emergency Compassionate Use Of Cholesterol Efflux Mediator VAR 200 In ApoCII Amyloidosis Patient
- Press releaseGlobe Newswire
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
- Press releaseGlobe Newswire
ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
ZyVersa Therapeutics CEO Highlights Recent PARASOL Recommendations To Accelerate Drug Development For FSGS, Announces Phase 2a Proof-Of-Concept Trial For VAR 200 In Diabetic Kidney Disease, And Discusses Potential Impact On Kidney Disease Treatment And Commercial Opportunities
- Press releaseGlobe Newswire
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
- NewsAvi Kapoor
S&P 500 Gains 1%; Vimeo Shares Spike Higher
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September
- NewsAvi Kapoor
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
- News
Market-Moving News for October 22nd
- NewsAvi Kapoor
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.